...
首页> 外文期刊>Oxidative Medicine and Cellular Longevity >Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients
【24h】

Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients

机译:抗氧化活性介导吡非尼酮对特发性肺纤维化患者血清暴露的人肺血管平滑肌细胞的抗纤维化作用

获取原文
           

摘要

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by an exacerbated fibrotic response. Although molecular and cellular determinants involved in the onset and progression of this devastating disease are largely unknown, an aberrant remodeling of the pulmonary vasculature appears to have implications in IPF pathogenesis. Here, we demonstrated for the first time that an increase of reactive oxygen species (ROS) generation induced by sera from IPF patients drives both collagen type I deposition and proliferation of primary human pulmonary artery smooth muscle cells (HPASMCs). IPF sera-induced cellular effects were significantly blunted in cells exposed to the NADPH oxidase inhibitor diphenyleneiodonium (DPI) proving the causative role of ROS and suggesting their potential cellular source. Contrary to IPF naive patients, sera from Pirfenidone-treated IPF patients failed to significantly induce both ROS generation and collagen synthesis in HPASMCs, mechanistically implicating antioxidant properties as the basis for the in vivo effect of this drug.
机译:特发性肺纤维化(IPF)是一种慢性肺疾病,其特征是纤维化反应加剧。尽管与这种破坏性疾病的发作和进展有关的分子和细胞决定因素基本上是未知的,但是肺血管系统的异常重塑似乎对IPF的发病机制有影响。在这里,我们首次证明了IPF患者血清诱导的活性氧(ROS)生成的增加既驱动了I型胶原蛋白的沉积,又促进了原代人肺动脉平滑肌细胞(HPASMC)的增殖。 IPF血清诱导的细胞作用在暴露于NADPH氧化酶抑制剂联苯二碘铵(DPI)的细胞中明显减弱,证明ROS具有致病作用并提示其潜在的细胞来源。与单纯使用IPF的患者相反,吡非尼酮治疗的IPF患者的血清不能显着诱导HPASMC中的ROS生成和胶原蛋白合成,从而在机械上暗示抗氧化剂特性是该药物体内作用的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号